Topics

Daewoong Pharmaceutical Co Ltd 069620 Product Pipeline Analysis, 2018 Uate [Report Updated: 19122018] Prices from USD $660

15:06 EST 4 Dec 2019 | BioPortfolio Reports

Summary


Daewoong Pharmaceutical Co Ltd Daewoong Pharma is one of the leading manufacturers and distributors of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, medical devices, cosmetics, health foods and APIs. The company produces products in the forms of tablets, capsules, ointments, injections, liquids and sprays. It offers its products for the therapeutic conditions of bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory remedies, among others. The company also carries out development and commercialization of products through inlicensing, comarketing and copromotion. It operates across Asia including Indonesia, China, Vietnam, Thailand and India; and the US. Daewoong Pharma is headquartered in Seoul, South Korea.


This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


Scope:


The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company Daewoong Pharmaceutical Co Ltd

The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.


Reasons to Buy:


Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research Development strategies

Develop marketentry and market expansion strategies

Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio


Note: Some sections may be missing if data is unavailable for the company

Original Article: Daewoong Pharmaceutical Co Ltd 069620 Product Pipeline Analysis, 2018 Uate [Report Updated: 19122018] Prices from USD $660

NEXT ARTICLE

More From BioPortfolio on "Daewoong Pharmaceutical Co Ltd 069620 Product Pipeline Analysis, 2018 Uate [Report Updated: 19122018] Prices from USD $660"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...